Biotechnology Company Hopes to Cure Hemophilia with Gene Editing
Fixx Pharmaceuticals Inc is a new biotechnology company launching on September 1, 2020. Fixx Pharmaceuticals is focused on developing therapies specifically targeted to treat patients suffering from bleeding disorders with the use of CRISPR gene editing.
One of Fixx's main areas of focus is Hemophilia. Hemophilia is an inherited bleeding disorder in which the blood does not clot properly. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally.
Jesse John Francis Clark, founder of Fixx Pharmaceuticals, is an internationally known professional, entrepreneur and passionate advocate for people living with Hemophilia and related bleeding disorders. Born with severe Hemophilia, Clark founded HemoAware Corporation in 2018, a non-profit organization dedicated to enriching the lives of people with inherited bleeding disorders through advocacy, education, and technology.
For more information visit www.FixxPharma.com
Contact: Jesse John Francis Clark
SOURCE: Fixx Pharmaceuticals, Inc.